Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


Severe neutropenia in African-descent patients treated with clozapine: results of a six-month, multinational open-label clinical trial

  • At: Seville (Spain) (2022)
  • Type: Poster
  • Poster code: HPS-071
  • By: PETERS, Olawunmi (Federal Neuro-psychiatric Hospital Yaba. Lagos, Nigeria)
  • Co-author(s): Mrs Olawunmi Peters, Director (Federal Neuro-psychiatric Hospital Yaba. Lagos, Lagos, Nigeria)
    Professor Deanna Kelly, Treatment Research Program (Maryland Psychiatric Recearch Center, University of Maryland, Maryland, United States)
    Dr Ikwunga Wonodi, Treatment Research Program (Maryland Psychiatric Recearch Center, University of Maryland, Maryland, United States)
    Dr Taiwo Oduguwa, Geriatric Psychiatry (Federal Neuro-psychiatric Hospital Yaba. Lagos, Lagos, Nigeria)
    Dr Richard Adebayo, Geriatric Psychiatry (Federal Neuro-psychiatric Hospital Yaba. Lagos, Lagos, Nigeria)
    Mr Ayodeji Olaniyan, Research (Federal Neuro-psychiatric Hospital Yaba. Lagos, Lagos, Nigeria)
    Mr Matthew Glassman, Treatment Research Program (Maryland Psychiatric Recearch Center, University of Maryland, Maryland, United States)
    Mrs Adeola Adebayo, Laboratory services (Federal Neuro-psychiatric Hospital Yaba. Lagos, Lagos, Nigeria)
  • Abstract:



    Background: Although clozapine is the most effective antipsychotic for treatment-resistant schizophrenia, it is markedly underutilized, particularly in the African American (AA) population. Low absolute neutrophil count (ANC), either at baseline or during treatment (ANC < 1500 cells/mm3), has been a significant barrier to clozapine use in AA..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 28 September 2023

FIP Congresses